ARTV: Allogeneic NK cell therapy for refractory RA shows strong efficacy, safety, and broad potential
The conference highlighted a novel allogeneic NK cell therapy for refractory RA, showing strong efficacy and safety, with a pivotal phase III trial underway and broad expansion potential. Key milestones include updated clinical data, retreatment insights, and progress toward additional indications…